<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428726</url>
  </required_header>
  <id_info>
    <org_study_id>NT-KO-003-2010-01</org_study_id>
    <nct_id>NCT01428726</nct_id>
  </id_info>
  <brief_title>A Phase IIa Study of NT-KO-003 for Multiple Sclerosis</brief_title>
  <official_title>A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotec Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advancell - Advanced In Vitro Cell Technologies, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurotec Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of
      relapsing remitting multiple sclerosis, comparing two doses versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IIa study, double blind, placebo Controlled, Multicenter Study that will
      involve up to 99 patients with relapsing remitting multiple sclerosis.

      After signing the informed consent form, subjects will be randomized to three treatments
      arms: placebo, NT-KO-003 low dose or NT-KO-003 high dose. Treatment will continue daily
      during 6 months. A MRI and a clinical evaluation will be performed monthly. Safety will be
      assessed during the 6 months treatment and until 15 days after the finalization of the
      treatment.

      Patients will be allowed to continue in the same arm of the study, in a blinded way, until
      the study finalizes as optional extension treatment. Patient will sign the Extension Informed
      Consent and a MRI will be performed for those patients still in treatment after 12 months of
      the inclusion in the core study (visit 0).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of NT-KO-003 in patients with relapsing remitting MS patients</measure>
    <time_frame>6 months</time_frame>
    <description>efficacy will be measured as the cumulative number of new lesions observed in all MRIs, with exception of baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of NT-KO-003 in relapsing remitting MS patients</measure>
    <time_frame>6 months</time_frame>
    <description>efficacy measured as the cumulative number of new lesions (gadolinium enhanced lesions and T2 lesions) in all MRIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of NT-KO-003 in relapsing remitting MS patients</measure>
    <time_frame>6 months</time_frame>
    <description>clinical efficacy will be measured as relapse rates and EDSS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of NT-KO-003 in patients with relapsing remitting MS patients</measure>
    <time_frame>six and a half months</time_frame>
    <description>safety will be measured as the incidence of adverse events and serious adverse events (incidence, causality, and severity) related to treatment with NT-KO-003</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-KO-003 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-KO-003 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-KO-003</intervention_name>
    <description>NT-KO-003 is a coated tablet, administered once a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>NT-KO-003 low dose</arm_group_label>
    <arm_group_label>NT-KO-003 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients who meet the diagnosis criteria for MS according to guidelines provided by
             McDonald et al (1)

          -  Patients who meet the diagnosis criteria for RRMS

          -  Patients with clinical disability measured by EDSS score between 0 and 5.0 inclusive

          -  Patients who present at least 1 relapse in the previous 2 years or presence of at
             least 1 gadolinium-enhanced lesion in the previous 1 year

          -  Patients aged between 18 to 55 years old, either gender

        Exclusion Criteria

          -  Patients who are candidates for treatment with drugs modifying the course of the
             disease according to the criteria of the Regulatory Agencies in each country, unless
             the patient refuses to initiate such therapy or decide to postpone the start of this
             therapy

          -  Patients with relapse in the 30 days period before baseline visit

          -  Patients in treatment with NT-KO-003

          -  Medical conditions such as hypotension, insulinoma, hyperuricemia

          -  Patients with Diabetes defined by ADA criteria (2)

          -  Other conditions: drug abuse, inability to consent, or inability to perform all the
             procedures for the Clinical Trial

          -  Contraindications for MRI studies: claustrophobia, heart pacemaker or any other
             condition that would preclude proximity to strong magnetic field

          -  Contraindications for treatment with NT-KO-003 or excipients: allergies,
             hypersensitivity

          -  Patients with known allergy or with contraindications to the administration of
             intravenous gadolinium-based agents (chronic or acute renal failure according to The
             Renal Association or NICE guidelines (3))

          -  Corticosteroid therapy in the last month

          -  Interferon-beta or Glatiramer acetate therapy in the last 3 months

          -  Natalizumab therapy in the last 6 months

          -  Patients treated with chemotherapy (Mitoxantrone, Azathioprine, Cyclophosphamide,
             Cladribine, Methotrexate) or monoclonal antibodies that deplete populations of cells
             (rituximab, alemtuzumab, ocrelizumab, daclizumab) in the last 12 months or have
             entered in previous trials with treatments in development in the last 3 months

          -  Patients participating in another Clinical Trial at the moment of the screening visit

          -  Patient who had received a liver transplantation or candidates for liver
             transplantation

          -  Positive pregnancy test, breast feeding women or of childbearing potential not using
             highly effective methods of contraception

          -  Male patients that do not follow adequate contraceptive measurements

          -  Fingolimod therapy in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Villoslada, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Studienzentrum an der Stiftung Deutsche Klinik für Diagnostik GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>March 15, 2014</last_update_submitted>
  <last_update_submitted_qc>March 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NT-KO-003</keyword>
  <keyword>RRMS</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>Phase IIa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

